| 1 2 | Fractional dosing to improve vaccination coverage, vaccine hesitancy, and cost- effectiveness in Africa: a systematic review |
|--------------------------|--|
| 3 | Short Title: Fractional dosing vaccine strategy and Africa |
| 4 5 6 7 | Abdourahamane Yacouba ^{1,2,*} , Souleymane Brah ^{1,2} , Maman Daou ^{1,2} , Abdoul-Kader Andia ^{,1,2} , Alkassoum Ibrahim ^{1,2} , Lamine Mahaman Moustapha ^{1,2} , Daouda Alhousseini ^{1,2} , Mahamadou Doutchi ^{1,2} , Ousmane Guindo ³ , Issaka Soumana ³ , Matthew E. Coldiron ⁴ , Saidou Mamadou ^{1,2} , Eric Adehossi ^{1,2} , Rebecca F. Grais ⁴ |
| 8 9 10 11 12 | Université Abdou Moumouni, Niamey, Niger Centre de Formation et de Recherche en Médecine Tropicale (CFRMT), Niamey, Niger Epicentre, Maradi, Niger Epicentre, 14-34 Avenue Jean Jaurès, Paris, France |
| 13 | *Corresponding author: abdourahamaneyacouba@yahoo.fr (YA) |
| 14 | |
| 15 | |
| 16 | |

17 Abstract

Background. The major challenges of vaccination programs are notably coverage in the target population, vaccine hesitancy, and cost-effectiveness. A vaccination strategy with fractional doses is a dose-saving strategy to address current vaccine shortages. Herein, we aimed to review the literature on administering fractional vaccine doses in Africa.

Methods. A methodical search of PubMed was conducted to identify articles published up till March 31, 2023. Peer-reviewed studies were selected for inclusion if they focused on studies that described the use of fractional doses of vaccines and were conducted in any of the 54 African countries.

26 **Results**. Findings from eleven eligible studies were analyzed. Studies were from the 27 Democratic Republic of the Congo, Gambia, Ghana, Kenya, South Africa, and Uganda. They 28 covered five vaccines including the yellow fever vaccine (n=3; 27.3%), inactivated poliovirus 29 vaccine (n=3; 27.3%), meningococcal A/C/Y/W135 vaccine (n=2; 18.2%), Haemophilus 30 *influenzae* type b vaccine (n=2; 18.2%), and malaria vaccine (n=1; 9.1%). Fractionated doses 31 used most often consist of one-fifth of the standard dose (n=8; 72.7%). Regarding 32 immunogenicity/efficacity, eight of ten studies that addressed immunogenicity suggest that 33 immune responses to the fractional dose vaccines were comparable to that of the standard 34 dose vaccines and resulted in higher antibody titers. Regarding safety, all of the eight studies 35 that addressed the safety of fractional doses in Africa, suggest that safety and tolerability data 36 of fractional dosing were favorable compared to full dose regimen.

37 **Conclusion**. Fractional dosing may be considered to address the availability and 38 acceptability of certain vaccines while maintaining protection. This strategy also has the 39 potential advantage of reducing the cost of vaccination programs, vaccine antigen overload, 40 and vaccine side effects.

41 Keywords: vaccine coverage; vaccine hesitancy; fractional doses, Africa

42 Introduction

43 Vaccination is acknowledged as the most effective and cost-effective means of 44 preventing and reducing the severity of infections [1,2]. Vaccination may further reduce the 45 magnitude epidemics and their consequences on hospital capacity by reducing case loads 46 thereby preserving the capacity of healthcare institutions to manage all acute and chronic 47 pathologies [3,4]. According to the World Health Organization (WHO), vaccination could 48 prevent 3.5 to 5 million deaths each year worldwide [5]. These numbers could increase by 1.5 49 million if global immunization coverage improves in all countries [5]. The expected effect of 50 the implementation of a vaccination campaign is to obtain vaccination coverage allowing for 51 the reduction in the circulation of the identified infectious agent in the population while 52 protecting individuals [6,7]. To achieve these goals, and derive maximum benefit, vaccination 53 coverage must reach certain critical levels for different pathogens if herd immunity is a goal 54 of the vaccination program [8].

According to WHO, reluctance or refusal to vaccinate is complex and does not depend on a simple set of individual factors [9]. It is important to understand these concerns and develop strategies to facilitate the acceptance of vaccination programs. In addition to the problem of vaccine refusal, some countries will face vaccine stock shortages with the global outbreak of epidemics straining the global vaccine supply [10,11].

Fractional dosing is a dose-saving approach under consideration to address vaccine stockouts
[12]. For example, in yellow fever, fractional dosing relies on the fact that the minimum
amount of virus required to achieve a protective titer of neutralizing antibody is 1000 IU
[13], whereas the standard vaccine dose typically contains ≥ 10,000 IU of the virus. Fractional

doses contain one-third or one-fifth or one-tenth or one-fiftieth of the standard dose. In practice, when a full-dose vaccine vial is used to deliver fractional doses, the number of doses in the vial is increased threefold or fivefold or tenfold: e.g., a vial containing 5 or 10 full doses becomes a vial of 25 or 50 fractional doses, respectively.

The objective of this review was to analyze the literature on the strategy of administering fractional doses of vaccines in Africa, focusing on efficacy, immunogenicity, and safety. Although efforts are currently underway to increase the possibility of vaccine manufacturing on the African continent, fractional dosing strategies may also be needed in the future and potentially offer other benefits.

73 Materials and Methods

74 Literature search

75 We searched PubMed to identify articles related to fractional doses of vaccines in 76 humans in Africa. Two authors (AY and BS) independently performed the literature search. 77 Keywords used for the search were "fractional doses" "fractional dosing", "Vaccines", 78 "Africa", and specific names of all African countries. The detailed search strategy can be 79 found in S1 Appendix file. A manual search for additional studies was performed using 80 references cited in original study articles and reviews. Additionally, studies were retrieved by 81 searches of the WHO vaccines and immunization Infobase. To avoid the inclusion of 82 duplicate studies, publications were cross-referenced considering the place and time period of 83 reported studies.

84 Study selection

85 Publications identified were considered up to March 31, 2023. Literature published 86 either in English or French was considered. Studies identified in the initial search were first 87 screened by title and abstract and retained if they met the predefined inclusion criteria, as 88 follows: (i) original article published in a peer-reviewed journal, (ii) studies that described the 89 use of fractional doses of vaccines, and (iii) studies conducted in any of the 54 Africa 90 countries. Expert opinions, review articles, modeling study, animal models, and protocols 91 were excluded. Publications were reviewed by two independent researchers (AY and BS) to 92 determine whether they met inclusion/exclusion criteria and if disagreement was arbitrated by 93 MD.

94 Data extraction

95 Information extraction was done using Microsoft Excel 2013 on a predesigned 96 database, developed for the purposes of this review. Data extracted included article 97 information (first author, year of publication, and country), study design (type of study, 98 sample size, age group), vaccines used, type of fractionated doses, and main findings. 99 Additionally, to address the immunogenicity of fractional doses of vaccines, a complementary 100 information including seroconversion percentage and geometric mean concentrations (GMC) 101 were extracted.

102 Data synthesis and analysis

103 A literature synthesis was performed based on the information gathered from the 104 analyzed publications. Qualitative data were presented as effective and proportion. Statistical 105 analyses and visualization were performed using R-software version 4.0.4. Summary figures 106 describing the main findings made using the Biorender application were 107 (https://app.biorender.com).

108 **Results**

109 Literature search

| 110 | A total of 183 potentially relevant articles on fractional dose vaccine strategy in Africa |
|-----|---|
| 111 | were identified in the initial electronic search. The titles and/or abstracts of 183 studies were |
| 112 | screened for relevance. Of the 183 studies screened, 152 studies were excluded and the |
| 113 | remaining 31 studies were retrieved for full text review. Ultimately, 11 studies were included |
| 114 | in this review (Fig 1). |

115 Fig 1. Flow diagram of the selection process of the included studies.

116 Data and study characteristics

- 117 Of the 11 studies included, two (18.2 %) were from Democratic Republic of the Congo
- 118 [16,17], two (18.2 %) from Gambia [18,19], two (18.2 %) from South Africa [20,21], three
- 119 (20.0 %) from Uganda [22–24], including one (9.1 %) performed in two countries, Uganda
- 120 and Kenya [24] (S1a Fig).
- 121 Vaccines fractionated in Africa were mostly yellow fever vaccine [16,17,24], (n=3; 27.3%)
- 122 and inactivated poliovirus vaccine [18,19,25], (n=3; 27.3%), followed by meningococcal
- 123 A/C/Y/W135 vaccine [22,23], (n=2; 18.2%) (Table 1).

124 Table 1. Vaccines fractionated in Africa

| Number | Percentage |
|--------|------------------|
| 2 | 18.2 |
| 3 | 27.3 |
| 1 | 09.1 |
| 2 | 18.2 |
| 3 | 27.3 |
| | 2 3 1 2 |

| | | Total | 11 | 100.0 |
|--|--|-------|----|-------|
|--|--|-------|----|-------|

125

| 126 | Fractionated doses used in Africa consist most often of one-fifth (1/5) of standard dose (n=8; |
|-----|---|
| 127 | 72,7%) [16–19,22–24,26]. Other dilution used as fractional doses included 1/10 [21–23] and |
| 128 | half (1/2) [25] of the full dose (Table 2). The result of distribution by time indicates that the |
| 129 | literature on fractional dosing strategy in Africa was first published in 2002 in South Africa |
| 130 | [21] (S1b Fig). Studies consisted of randomized and controlled trials [17-26] (n=10; 90,9%) |
| 131 | and community-based pharmacovigilance [16] (n=1; 9.1%). Of the randomized trial, half |
| 132 | (5/10) were non-inferiority trial (Table 2). |

| | | | | | | | Immunogenicity | | | |
|-------------------------------|---|--|-----------------------------------|------------------------|------------------------------|--|--|--|-------------------------|-----------------|
| Reference | country | vaccines | Type of study | Participants number | Intervention | Seroconversion, %(CI 95%) | Geometric mean concentrations (GMC) in lg/ ml(CI 95%) | Findings | Long term protection | Safety |
| Casey et al. 2019 [17] | Democra tic Republic of the Congo | Yellow fever | randomized controlled trial | 764 | 1/5 of standard dose | In one month: 98 % [96–99]; In one year: 96 % [94–98] | In one month: 1340 (1117– 1607); In one year: 143 (123–166) | The immunologic response to a fractional dose of the 17DD yellow fever vaccine was appropriate for a response to a yellow fever outbreak among children 2 years of age or older and among nonpregnant adults | Not reported | Not reported |
| Barnes et al. 2011 [23] | Uganda | <u>Menomunefr</u> om Sanofi <u>Pasteur, a</u> <u>tetravalent</u> <u>AC/Y/W135</u> polysacchari <u>de vaccine</u> | randomized controlled trial | 115 | 1/5 and 1/10 of full dose | Not reported | 1 month after the first dose: 1/10 of full dose 43.3 (36.5–51.4) 1/5 of full dose 44.6 (38.4–51.8) | Fractional doses are able to elicit antibodies of as good avidity against serogroup A polysaccharide as a full dose | Not reported | Not reported |

Table 2: Mains findings related to fractional doses vaccination in Africa

| Bashorun et al. 2022 [19] | Gambia | Inactivated poliovirus vaccine | pragmatic, open-label, non- inferiority trial | 3170 | 1/5 of full dose | Polyovirus 1: 88·3% (80·6– 93·1) Polyovirus 2: 100·0% (93·1– 100·0) Polyovirus 3: 81·9% (76·5– 86·1) | Polyovirus 1: ≥1448 (1448– 1448) Polyovirus 2: ≥1448 (1448– 1448) Polyovirus 3: ≥1448 (1448– 1448) | Non-inferiority was demonstrated between the full dose and fractional doses when administered with an BCG needle and syringe, a disposable syringe jet injector, and an intradermal adaptor | Not reported | Safety andtolera bility data were favorable |
|---------------------------------|--------|--------------------------------------|---|------|------------------------------|--|--|--|-----------------|---|
| Clarke et al. 2016 [18] | Gambia | Inactivated poliovirus vaccine | randomized, non- inferiority trial | 182 | 1/5 of full dose (0.1 ml) | Polyovirus 1: 86·4% (66·7–95·3) Polyovirus 2: 100·0% (67·6–100·0) Polyovirus 3: 90·4% (79·4–95·8) Measle: | Not reported | fractional doses did not achieve non-inferiority compared with full dose | Not reported | Safety andtolera bility data were favorable |

9

| Guerin et al. 2008 [22] | Uganda | A/C/Y/W13 5 polysacchari de meningococ cal vaccine | Randomized Non- Inferiority Controlled Trial rrial | 750 | 1/10, 1/5 of full dose | PerProtocol (PP) population1/5 of full doseSerogroup A : 77.5 (72.0– 83.0)Serogroup W135 : 94.6 (91.6– 97.6)Serogroup C : 80.4 (75.2– 85.6)Serogroup Y : 82.4 (77.4– 87.4)1/10 of full doseSerogroup A : 69.4 (63.5– 75.3)Serogroup W135 : 95.6 (93.0– 98.2)Serogroup C : 76.6 (71.1– 82.1)Serogroup Y : 83.9 (79.2–88.6) | PerProtocol (PP) population1/5 of full doseSerogroup A : 2054.4 (1612.2– 2618.0)Serogro up W135 : 2041.6 (1582.2– 2634.5)Serogro up C : 467.3 (328.0– 665.8)Serogrou p Y : 768.3 (524.4– 1125.6)1/10 of full doseSerogroup A : 1369.3 (1083.3– 1730.7)Serogro up W135 : 2426.3 (1979.7– 2973.7)Serogro up C : 396.3 (274.6– 572.0)Serogrou p Y : 816.8 565.1–1180.8 Not reported | Non-inferiority was demonstrated between the full dose and fractional doses against serogroups W135, Y and A. Fractional doses did not achieve non-inferiority compared with full dose for serogroup C. | Not reported | Safety andtolera bility data were favorable |
|-------------------------------|--------|---|---|-----|---------------------------|--|--|--|-----------------|---|
| al. 2020 [25] | que | type 2 oral poliovirus vaccine (mOPV2) | controlled, open-label, noninferiorit y trial | 570 | dose | 62.1%) | Tion reported | did not achieve non-inferiority compared with full dose | reported | reported |

| Huebner et al. 2004 [20] | South Africa | Haemophilu s influenzae type b vaccine conjugated either to diphtheria CRM197 (Chiron, Sienna, Italy) or tetanus toxoid (Berna Biotech Ltd., Berne, Switzerland) | randomized trial | 168 | 1/16; 1/8; 1/4; 1/2 of full dose | 1/8 of full dose 100 % (95–100) | 1/8 of full dose 6.33 (4.21–9.50) | vaccines of ≥1.25 µg (1/8 of full dose) may be sufficient to stimulate an immune response that offers both short and longer- term protection from invasive Hib disease | Offer longer- term protection from invasive Hib disease | Safety andtolera bility data were favorable |
|--------------------------------|-----------------|--|---------------------|-----|--|---|---|--|--|---|
| Nicol et al. 2002 [21] | South Africa | Haemophilu s influenzae type b polysacchari de-tetanus toxoid conjugate (PRP-T) vaccine | randomized trial | 168 | 1/10 of full dose | 94% | Not reported | The 1/10 dose of PRP-T was as immunogenic as the full dose. | Not reported | Safety andtolera bility data were favorable |

| Juan-Giner et al. 2021 [24] | Kenya and Uganda | Yellow fever: 17DD Bio- Manguinhos -Fiocruz, 17D-213 Chumakov Institute of Poliomyeliti s and Viral Encephalitid es , 17D-204 Institut Pasteur Dakar, 17D- 204 Sanofi Pasteur | randomized, double- blind, non- inferiority trial | 960 | 1/5 of full dose | Day 28 17DD Bio- Manguinhos- Fiocruz: 100·0 % (96·7 to 100·0);17D-213 Chumakov Institute of Poliomyelitis and Viral Encephalitides: 99·1% (95·1 to 100·0); 17D-204 Institut Pasteur Dakar: 100·0 % (96·8 to 100·0); 17D-204 Sanofi Pasteur: 100·0 % (96·8 to 100·0) | Day 28 17DD Bio- Manguinhos- Fiocruz: 3939 (2812, 5516);17D-213 Chumakov Institute of Poliomyelitis and Viral Encephalitides: 5874 (4162 to 8289); 17D-204 Institut Pasteur Dakar: 4279 (3182 to 5753); 17D-204 Sanofi Pasteur: 5545 (4106, 7488) | non-inferior to the standard dose in inducing seroconversion 28 days after vaccination | Not reported | Safety andtolera bility data were favorable |
|-----------------------------------|------------------------|---|---|------|---------------------|---|---|---|-----------------|---|
| Samuels et al. 2022 [26] | Ghana | Malaria vaccine | randomized controlled trial | 2157 | 1/5 of full dose | Not reported | Not reported | 1/5 of full dose regimen does not affect protective efficacy over | Not reported | Safety and tolerabili ty data were favorable |

| Nzolo et | Democra | 17DD | Community- | 4020 | 1/5 of full | Not reported | Not reported | Not reported | Not | Safety |
|----------|----------|---------|-------------|------|-------------|--------------|--------------|--------------|----------|------------|
| al. 2018 | tic | Yellow | based | | dose | | | | reported | and |
| [16] | Republic | Fever | pharmacovig | | | | | | | tolerabili |
| | of the | Vaccine | ilance | | | | | | | ty data |
| | Congo | | | | | | | | | were |
| | | | | | | | | | | favorable |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |

Advantages of fractional doses strategy

Evidence synthesis on the advantages of fractional dosing strategy highlighted that in addition to the reduction of vaccine antigen overload, reduction of vaccine cost, reduction of stock-outs, and long-term durable protection, fractional doses retain their immunogenicity and have good safety and efficacy profiles (Fig 2).

Fig 2. Advantages of vaccination using fractional dosing strategy.

Immunogenicity and efficiency of fractional dosing strategy

Ten of eleven studies [17–26] addressed immunogenicity of fractional doses strategy in Africa. Of the ten, two studies [18,25] did not establish non-inferiority of the fractional dose strategy compared with a full dose (Table 2). In one study [26], authors reported that 1/5 of the full dose was as effective as the standard dose of the malaria vaccine (Table 2). Evidence from eight studies [17,19–24] suggests that the fractional dosing strategy could yield high immune responses, comparable to those for standard doses of the same vaccine (Table 2). These authors support the use of fractional dose vaccination for outbreak control [17,19–24].

Safety of fractional dosing strategy

Eight of eleven (72.7%) studies [16,18–22,24,26] addressed the safety of fractional doses strategy in Africa. All of them suggest that safety and tolerability data of fractional dosing were favorable compared to the full dose regimen.

Discussion

The use of a fractional dosing strategy is a well-known strategy [12,27,28]. Our study demonstrated that a fractional dosing strategy may be as sufficient to stimulate an immune as a standard dose of vaccine. This means that, for yellow fever, inactivated poliovirus, A/C/Y/W135 polysaccharide meningococcal, and Haemophilus influenzae type b vaccines, immunogenicity data suggest that 1/5 or 1/10 doses could be almost as efficacious as standard dose used of the same vaccines. Authors reported that the 1/5 of standard dose of the 17DD Yellow fever vaccines was effective at inducing seroconversion in 98% of the participants who were seronegative at baseline, which is similar between gender [17]. In a recent study, seroconversion rates at four to five weeks following vaccination were similar between participants who received standard doses and participants who received fractional doses containing one-third, one-fifth, one-tenth, and one-fiftieth of the standard dose [12]. Among the immunological mechanisms proposed to explain this phenomenon, one can cite the fact that dose fractionation favors the persistence of antigen-specific B lymphocytes [29]. The increase in somatic hypermutation and antibody avidity [30,31] has high responses to immunoglobulin G class 4 [32] and higher neutralizing antibody titers [33]. Additionally, fractional doses may also have less side effects [34], vaccine antigen overload, cost, and stock-outs [35,36,17] than standard dose. Vaccine shortages and stockouts during outbreaks happen frequently in underdeveloped countries, and occasionally in developed countries [37– 40]. In a country, the shortage/stockout events can occur at the national and at subnational level. The most frequently reported causes vaccine shortages/stockouts in Africa include global shortage, disease outbreaks, poor stock management, poor supply chain structure, delays in deliveries, lack of trained health personnel, and lack of resource to purchase vaccine [41,42]. Typically, to address vaccine shortages/stockouts, actions undertaken by African

countries were to purchase additional doses of the vaccine from other supplier/manufacturer, the use of available stockpiles of vaccine, to redistribute stock doses among regions and facilities, to import vaccine from another country, or to contact WHO (or other institutions) for technical assistance. On top of that, using lower doses of vaccine is one such action [17]. Currently, the fractional-dose strategy is emerging as an alternative option for urgently stretching restricted vaccines supplies [10,11,35]. WHO supports the use of fractional doses strategy for yellow fever as part of an emergency response to an epidemic if the shortage of full doses exceeds the capacity of the global stockpile [36]. Many countries in developed and underdeveloped countries have experimented with the use of fractional doses to address vaccine shortages [10,11,35].

Studies showed that one of the most serious concerns influencing vaccination acceptance are about side effects [43–45]. Individuals or parents were concerned about potential side effects of vaccines [46]. According to Saied et al. [43] in Egypt, 96.8% of the participants of their study had concerns regarding the vaccine's adverse effects [43]. In a community based-pharmacovigilance, fractional dosing of 17DD Yellow fever vaccine has a good tolerability and safety profile, which is almost similar between females and males [16]. Fractional doses of the same vaccine may be superior if they offer comparable efficacy with lesser side effects. If efficacy is comparable to that of standard doses, and side effects are lesser, fractional doses might be superior to current doses in terms of individual benefit–risk profile.

Fractional doses strategy to address vaccination coverage in Africa

Childhood vaccination is one of the fundamental strategies for achieving goal three of the Sustainable Development Goals (SDGs), which is to reduce under-five mortality to less than 25/1000 live births by 2030 [47]. In Africa, vaccination coverage is lagging behind the

90% target set in the regional strategic plan for vaccination 2014-2020 [8]. As an example, vaccination coverage remained low in 2017 for DTP3 (72%), PCV3 (68%), Hib3 (72%), MCV1 (70%), and RCV1 (26%) [48]. Many barriers exist to achieving good vaccination coverage in Africa, including factors associated with vaccine hesitancy.

Fractional doses strategy to address vaccine hesitancy

There are several possible reasons for vaccine refusal (Fig 3). The main factors are religion, parental distrust, dissemination of misinformation, and anti-vaccine movements. According to WHO, vaccine hesitancy or refusal is the 8th most prevalent health threat after pollution and climate, non-communicable diseases, pandemic influenza, vulnerable countries, antimicrobial resistance, Ebola and high-risk pathogens, and primary health care [49,50]. Vaccination denial dates back to the first vaccine administered in humans, the smallpox vaccine [51].

Parents' decisions about whether or not to vaccinate their children are complex and multidimensional. However, the main parent-specific factor most often involved in their experience with vaccination (side effects) [52–56]. In addition to keeping parents away from the vaccine, the presence of side effects could amplify the spread of misinformation about the vaccine anti-vaccine movements. Fractional dose strategies may resolve this issue by reducing the side effects of the vaccines compared to full dose [12,24,57–61].

The rise of well-organized anti-vaccine movements is currently a serious threat to vaccination programs in both developed and developing countries. The main concerns put forward by the anti-vaccine community were antigenic overload [62,63], autoimmunity [64–68]. By reducing vaccine antigen overload compared to full dose regimen, fractionated doses strategy may address this issue.

Cost-effectiveness analyses are critical to planning vaccination campaign financing decisions. It is a measure of the amount of money needed to fund an vaccination project and achieve the previously defined goal. Fractional doses vaccines could be an economically viable vaccination strategy compared to full-dose vaccination or no vaccination [69]. Additionally, fractional doses vaccines strategy could save a large number of lives, and for mitigated the public health costs of resurgences after vaccination [70].

Fig 3. Main factors behind vaccine hesitancy.

Strengths and Limitations

To the best of our knowledge, this study is the first to review the vaccination strategy with fractional doses strategy in Africa, a topic with potential significant public health impact. However, it is limited by the relatively few publications on fractional dosing strategy in Africa that may impact generalizability. Another flaw in the current systematic review that may impact generalizability is that the majority of the studies are from the Southern Africa. There is, therefore a need for a continuous update, especially on the impact of fractional dosing strategy on vaccine hesitancy, as new evidence emerges. Another shortcoming is that meta-analysis is not performed, which might impact power to study the factors associated to fractional dose strategy. Even then, this study synthesized the current state and should help inform policy decision-making and research needs for fractional dosing strategy in Africa.

Conclusion

In Africa, despite the progress made in recent years in the various immunization programs, vaccination coverage is far from reaching the 90% target. Various complex factors are at the origin of vaccine hesitancy. The use of fractional doses vaccine strategy could be a

solution to improve the availability and acceptability of vaccines while saving costs, reducing

side effects, and maintaining efficacy, immunogenicity, and long- term protection.

References

- 1. Ada G. The importance of vaccination. Frontiers in Bioscience-Landmark. 2007;12: 1278–1290. doi:10.2741/2146
- 2. Wahl B, O'Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. The Lancet Global Health. 2018;6: e744–e757. doi:10.1016/S2214-109X(18)30247-X
- 3. Kirwan PD, Charlett A, Birrell P, Elgohari S, Hope R, Mandal S, et al. Trends in COVID-19 hospital outcomes in England before and after vaccine introduction, a cohort study. Nat Commun. 2022;13: 4834. doi:10.1038/s41467-022-32458-y
- Pacetti G, Baronc-Adesi F, Corvini G, D'Anna C, Schmid M. Use of a modified SIR-V model to quantify the effect of vaccination strategies on hospital demand during the Covid-19 pandemic. 2022 44th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC). 2022. pp. 4695–4699. doi:10.1109/EMBC48229.2022.9871957
- 5. WHO. Vaccins et vaccination. [cited 25 Oct 2022]. Available: https://www.who.int/fr/health-topics/vaccines-and-immunization
- Usuf E, Bottomley C, Adegbola RA, Hall A. Pneumococcal Carriage in Sub-Saharan Africa—A Systematic Review. PLOS ONE. 2014;9: e85001. doi:10.1371/journal.pone.0085001
- 7. Dube FS, Ramjith J, Gardner-Lubbe S, Nduru P, Robberts FJL, Wolter N, et al. Longitudinal characterization of nasopharyngeal colonization with Streptococcus pneumoniae in a South African birth cohort post 13-valent pneumococcal conjugate vaccine implementation. Sci Rep. 2018;8: 12497. doi:10.1038/s41598-018-30345-5
- Comité régional de l'Afrique 64. Plan stratégique régional pour la vaccination 2014-2020 : Rapport du Secrétariat. OMS. Bureau régional de l'Afrique; 2014 Nov. Report No.: AFR/RC64/5. Available: https://apps.who.int/iris/handle/10665/145535
- 9. Jacobson RM, St. Sauver JL, Finney Rutten LJ. Vaccine Hesitancy. Mayo Clinic Proceedings. 2015;90: 1562–1568. doi:10.1016/j.mayocp.2015.09.006
- Ebrahim SH, Assiri AM, Memish ZA. Meningitis vaccine shortage and the 2019 Hajj mass gathering: market dynamics and epidemic control. Journal of Travel Medicine. 2019;26: taz039. doi:10.1093/jtm/taz039
- 11. Sutter RW, Cochi SL. Inactivated Poliovirus Vaccine Supply Shortage: Is There Light at the End of the Tunnel? The Journal of Infectious Diseases. 2019;220: 1545–1546. doi:10.1093/infdis/jiy739
- Nnaji CA, Shey MS, Adetokunboh OO, Wiysonge CS. Immunogenicity and safety of fractional dose yellow fever vaccination: A systematic review and meta-analysis. Vaccine. 2020;38: 1291–1301. doi:10.1016/j.vaccine.2019.12.018

- 13. WHO. Fractional dose yellow fever vaccine as a dose-sparing option for outbreak response. 2016 [cited 16 Aug 2023]. Available: https://www.who.int/publications-detail-redirect/WHO-YF-SAGE-16-1
- 14. Study Quality Assessment Tools | NHLBI. 2021 [cited 17 Aug 2023]. Available: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
- 15. Newcastle-Ottawa Quality Assessment Scale (adapted for cross sectional studies). Available: https://journals.plos.org/plosone/article/file?type=supplementary&id= info:doi/10.1371/journal.pone.0147601.s001
- Nzolo D, Engo Biongo A, Kuemmerle A, Lusakibanza M, Lula Y, Nsengi N, et al. Safety profile of fractional dosing of the 17DD Yellow Fever Vaccine among males and females: Experience of a community-based pharmacovigilance in Kinshasa, DR Congo. Vaccine. 2018;36: 6170–6182. doi:10.1016/j.vaccine.2018.08.052
- Casey RM, Harris JB, Ahuka-Mundeke S, Dixon MG, Kizito GM, Nsele PM, et al. Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak - Final Report. N Engl J Med. 2019;381: 444–454. doi:10.1056/NEJMoa1710430
- Clarke E, Saidu Y, Adetifa JU, Adigweme I, Hydara MB, Bashorun AO, et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia. Lancet Glob Health. 2016;4: e534-547. doi:10.1016/S2214-109X(16)30075-4
- 19. Bashorun AO, Badjie Hydara M, Adigweme I, Umesi A, Danso B, Johnson N, et al. Intradermal administration of fractional doses of the inactivated poliovirus vaccine in a campaign: a pragmatic, open-label, non-inferiority trial in The Gambia. Lancet Glob Health. 2022;10: e257–e268. doi:10.1016/S2214-109X(21)00497-6
- 20. Huebner RE, M N, R M, H K, N M, E K, et al. Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines. Vaccine. 2004;23: 802–806. doi:10.1016/j.vaccine.2004.06.052
- 21. Nicol M, Huebner R, Mothupi R, Käyhty H, Mbelle N, Khomo E. Haemophilus influenzae type b conjugate vaccine diluted tenfold in diphtheria-tetanus-whole cell pertussis vaccine: a randomized trial. The Pediatric Infectious Disease Journal. 2002;21: 138.
- 22. Guerin PJ, Næss LM, Fogg C, Rosenqvist E, Pinoges L, Bajunirwe F, et al. Immunogenicity of Fractional Doses of Tetravalent A/C/Y/W135 Meningococcal Polysaccharide Vaccine: Results from a Randomized Non-Inferiority Controlled Trial in Uganda. PLOS Neglected Tropical Diseases. 2008;2: e342. doi:10.1371/journal.pntd.0000342
- 23. Bårnes GK, Naess LM, Rosenqvist E, Guerin PJ, Caugant DA, Fractional Doses Vaccine Study Group. Avidity of serogroup A meningococcal IgG antibodies after immunization with different doses of a tetravalent A/C/Y/W135 polysaccharide vaccine. Scand J Immunol. 2011;74: 87–94. doi:10.1111/j.1365-3083.2011.02535.x

- 24. Juan-Giner A, Kimathi D, Grantz KH, Hamaluba M, Kazooba P, Njuguna P, et al. Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial. The Lancet. 2021;397: 119–127. doi:10.1016/S0140-6736(20)32520-4
- 25. de Deus N, Capitine IPU, Bauhofer AFL, Marques S, Cassocera M, Chissaque A, et al. Immunogenicity of Reduced-Dose Monovalent Type 2 Oral Poliovirus Vaccine in Mocuba, Mozambique. J Infect Dis. 2020;226: 292–298. doi:10.1093/infdis/jiaa704
- 26. Samuels AM, Ansong D, Kariuki SK, Adjei S, Bollaerts A, Ockenhouse C, et al. Efficacy of RTS,S/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5–17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial. The Lancet Infectious Diseases. 2022;22: 1329–1342. doi:10.1016/S1473-3099(22)00273-0
- 27. Gamage D, Ginige S, Palihawadana P. National introduction of fractional-dose inactivated polio vaccine in Sri Lanka following the global "switch." WHO South-East Asia Journal of Public Health. 2018;7: 79. doi:10.4103/2224-3151.239418
- Schnyder JL, De Pijper CA, Garcia Garrido HM, Daams JG, Goorhuis A, Stijnis C, et al. Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination - A systematic review and meta-analysis. Travel Medicine and Infectious Disease. 2020;37: 101868. doi:10.1016/j.tmaid.2020.101868
- 29. Pallikkuth S, Chaudhury S, Lu P, Pan L, Jongert E, Wille-Reece U, et al. A delayed fractionated dose RTS,S AS01 vaccine regimen mediates protection via improved T follicular helper and B cell responses. Krzych U, Soldati-Favre D, editors. eLife. 2020;9: e51889. doi:10.7554/eLife.51889
- Mottram L, Lundgren A, Svennerholm A-M, Leach S. Booster vaccination with a fractional dose of an oral cholera vaccine induces comparable vaccine-specific antibody avidity as a full dose: A randomised clinical trial. Vaccine. 2020;38: 655–662. doi:10.1016/j.vaccine.2019.10.050
- Regules JA, Cicatelli SB, Bennett JW, Paolino KM, Twomey PS, Moon JE, et al. Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study. J Infect Dis. 2016;214: 762–771. doi:10.1093/infdis/jiw237
- 32. Chaudhury S, Regules JA, Darko CA, Dutta S, Wallqvist A, Waters NC, et al. Delayed fractional dose regimen of the RTS,S/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosis. Sci Rep. 2017;7: 7998. doi:10.1038/s41598-017-08526-5
- Ma Y, Ying Z, Li J, Gu Q, Wang X, Cai L, et al. Immunogenicity of fractional-dose of inactivated poliomyelitis vaccine made from Sabin strains delivered by intradermal vaccination in Wistar rats. Biologicals. 2022;75: 3–11. doi:10.1016/j.biologicals.2022.01.005
- 34. Resik S, Tejeda A, Mas Lago P, Diaz M, Carmenates A, Sarmiento L, et al. Randomized Controlled Clinical Trial of Fractional Doses of Inactivated Poliovirus Vaccine

Administered Intradermally by Needle-Free Device in Cuba. The Journal of Infectious Diseases. 2010;201: 1344–1352. doi:10.1086/651611

- Teitelbaum P, Bui Y-G, Libman M, McCarthy A. Fractional dosing of yellow fever vaccine during shortages: perspective from Canada. Journal of Travel Medicine. 2018;25: tay098. doi:10.1093/jtm/tay098
- 36. World Health Organization. WHO position on the use of fractional doses June 2017, addendum to vaccines and vaccination against yellow fever WHO: Position paper June 2013. Vaccine. 2017;35: 5751–5752. doi:10.1016/j.vaccine.2017.06.087
- Chen LH, Kozarsky PE, Visser LG. What's Old Is New Again: The Re-emergence of Yellow Fever in Brazil and Vaccine Shortages. Clinical Infectious Diseases. 2019;68: 1761–1762. doi:10.1093/cid/ciy777
- 38. Lucey DR, Donaldson H. Yellow Fever Vaccine Shortages in the United States and Abroad: A Critical Issue. Ann Intern Med. 2017;167: 664–665. doi:10.7326/M17-1337
- Ziesenitz VC, Mazer-Amirshahi M, Zocchi MS, Fox ER, May LS. U.S. vaccine and immune globulin product shortages, 2001–15. American Journal of Health-System Pharmacy. 2017;74: 1879–1886. doi:10.2146/ajhp170066
- 40. Miranda-García MA, Hoffelner M, Stoll H, Ruhaltinger D, Cichutek K, Siedler A, et al. A 5-year look-back at the notification and management of vaccine supply shortages in Germany. Eurosurveillance. 2022;27: 2100167. doi:10.2807/1560-7917.ES.2022.27.17.2100167
- Iwu CJ, Ngcobo N, Jaca A, Wiyeh A, Pienaar E, Chikte U, et al. A systematic review of vaccine availability at the national, district, and health facility level in the WHO African Region. Expert Review of Vaccines. 2020;19: 639–651. doi:10.1080/14760584.2020.1791088
- 42. Hinman AR, Orenstein WA, Santoli JM, Rodewald LE, Cochi SL. Vaccine shortages: History, Impact, and Prospects for the Future. Annual Review of Public Health. 2006;27: 235–259. doi:10.1146/annurev.publhealth.27.021405.102248
- 43. Saied SM, Saied EM, Kabbash IA, Abdo SAE-F. Vaccine hesitancy: Beliefs and barriers associated with COVID-19 vaccination among Egyptian medical students. Journal of Medical Virology. 2021;93: 4280–4291. doi:10.1002/jmv.26910
- 44. Otieno NA, Otiato F, Nyawanda B, Adero M, Wairimu WN, Ouma D, et al. Drivers and barriers of vaccine acceptance among pregnant women in Kenya. Human Vaccines & Immunotherapeutics. 2020 [cited 24 Apr 2023]. Available: https://www.tandfonline.com/doi/abs/10.1080/21645515.2020.1723364
- 45. Ackah BBB, Woo M, Stallwood L, Fazal ZA, Okpani A, Ukah UV, et al. COVID-19 vaccine hesitancy in Africa: a scoping review. glob health res policy. 2022;7: 1–20. doi:10.1186/s41256-022-00255-1
- 46. Njidda UM, Kever R, Lola N, Dathini H, Mshelia A. Assessment of parents knowledge towards the benefits of child immunization in Maiduguri, Borno State, Nigeria. Nurse Care Open Acces J. 2017;3: 226□239.

- 47. GBD 2017 SDG Collaborators. Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England). 2018;392. doi:10.1016/S0140-6736(18)32281-5
- 48. VanderEnde K, Gacic-Dobo M, Diallo MS, Conklin LM, Wallace AS. Global Routine Vaccination Coverage — 2017. MMWR Morb Mortal Wkly Rep. 2018;67: 1261–1264. doi:10.15585/mmwr.mm6745a2
- 49. Manus J-M. Dix menaces à la santé mondiale en 2019. Rev Francoph Lab. 2019;2019: 20–21. doi:10.1016/S1773-035X(19)30217-5
- 50. Ten health issues WHO will tackle this year. [cited 25 Oct 2022]. Available: https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019
- 51. Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent). 2005;18: 21–25.
- 52. Gowda C, Dempsey AF. The rise (and fall?) of parental vaccine hesitancy. Human Vaccines & Immunotherapeutics. 2013;9: 1755–1762. doi:10.4161/hv.25085
- Kunieda MK, Manzo ML, Subramanian SV, Jimba M. Individual- and Neighborhood-Level Factors of Measles Vaccination Coverage in Niamey, Niger: A Multilevel Analysis. Vaccines. 2022;10: 1513. doi:10.3390/vaccines10091513
- Musa S, Dergaa I, Abdulmalik MA, Ammar A, Chamari K, Saad HB. BNT162b2 COVID-19 Vaccine Hesitancy among Parents of 4023 Young Adolescents (12–15 Years) in Qatar. Vaccines. 2021;9: 981. doi:10.3390/vaccines9090981
- 55. Sabahelzain MM, Moukhyer M, van den Borne B, Bosma H. Vaccine Hesitancy among Parents and Its Association with the Uptake of Measles Vaccine in Urban Settings in Khartoum State, Sudan. Vaccines. 2022;10: 205. doi:10.3390/vaccines10020205
- Tankwanchi AS, Bowman B, Garrison M, Larson H, Wiysonge CS. Vaccine hesitancy in migrant communities: a rapid review of latest evidence. Current Opinion in Immunology. 2021;71: 62–68. doi:10.1016/j.coi.2021.05.009
- 57. Więcek W, Ahuja A, Chaudhuri E, Kremer M, Simoes Gomes A, Snyder CM, et al. Testing fractional doses of COVID-19 vaccines. Proceedings of the National Academy of Sciences. 2022;119: e2116932119. doi:10.1073/pnas.2116932119
- Roozen GVT, Prins MLM, van Binnendijk R, den Hartog G, Kuiper VP, Prins C, et al. Safety and Immunogenicity of Intradermal Fractional Dose Administration of the mRNA-1273 Vaccine: A Proof-of-Concept Study. Ann Intern Med. 2022;175: 1771– 1774. doi:10.7326/M22-2089
- 59. Yang B, Huang X, Gao H, Leung NH, Tsang TK, Cowling BJ. Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and metaanalysis. BMC Med. 2022;20: 409. doi:10.1186/s12916-022-02600-0
- 60. Intapiboon P, Seepathomnarong P, Ongarj J, Surasombatpattana S, Uppanisakorn S, Mahasirimongkol S, et al. Immunogenicity and Safety of an Intradermal BNT162b2

mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population. Vaccines. 2021;9: 1375. doi:10.3390/vaccines9121375

- 61. Staples JE, Alvarez A-MR. Public health role for fractional dosage of yellow fever vaccine. The Lancet. 2021;397: 76–77. doi:10.1016/S0140-6736(20)32707-0
- 62. Gregson AL, Edelman R. Does antigenic overload exist? The role of multiple immunizations in infants. Immunology and Allergy Clinics. 2003;23: 649–664. doi:10.1016/S0889-8561(03)00097-3
- 63. Hulsey E, Bland T. Immune overload: Parental attitudes toward combination and single antigen vaccines. Vaccine. 2015;33: 2546–2550. doi:10.1016/j.vaccine.2015.04.020
- 64. Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Adjuvants and autoimmunity. Lupus. 2009;18: 1217–1225. doi:10.1177/0961203309345724
- 65. Salemi S, D'Amelio R. Could Autoimmunity Be Induced by Vaccination? International Reviews of Immunology. 2010;29: 247–269. doi:10.3109/08830181003746304
- 66. Segal Y, Shoenfeld Y. Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction. Cell Mol Immunol. 2018;15: 586–594. doi:10.1038/cmi.2017.151
- 67. Squeri R. HPV vaccine and autoimmune diseases: systematic review and meta-analysis of the literature. Journal of Preventive Medicine and Hygiene. 2018;59: E194–E194. doi:10.15167/2421-4248/jpmh2018.59.3.998
- 68. Vaccines, adjuvants and autoimmunity. Pharmacological Research. 2015;100: 190–209. doi:10.1016/j.phrs.2015.08.003
- 69. Du Z, Wang L, Pandey A, Lim WW, Chinazzi M, Piontti AP y, et al. Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India. Nat Med. 2022;28: 934–938. doi:10.1038/s41591-022-01736-z
- Cowling BJ, Lim WW, Cobey S. Fractionation of COVID-19 vaccine doses could extend limited supplies and reduce mortality. Nat Med. 2021;27: 1321–1323. doi:10.1038/s41591-021-01440-4

Supporting information

S1 Fig. Country (a) and time distribution (b) of studies on fractional doses vaccines.





